Life Science Tax Credits

For business owners, the key takeaway is that life science tax credits are a direct lever on cash flow and runway.

By properly identifying qualified R&D activities and costs, companies can convert a meaningful portion of their spend into immediate tax savings or even cash via payroll offsets, which is especially critical in pre-revenue stages.

Coordinating these credits with Section 174 rules, state incentives, and long-term strategies like QSBS can significantly reduce overall tax burden while preserving capital for growth. The difference between treating this proactively versus as an afterthought often translates into hundreds of thousands—or more—in retained capital.

Life science companies—across biotech, medtech, diagnostics, and digital health—invest heavily in experimentation long before generating revenue. The tax code is designed to offset that burden through credits, deductions, and cash refunds, effectively turning R&D spend into a financing tool. The federal R&D tax credit (IRC §41) allows companies to claim 6–10% of qualified research expenses, including wages, supplies, and a portion of contract research. These credits can be used to offset income taxes or, for startups, payroll taxes—often providing immediate cash flow. Proper documentation of technical uncertainty and experimentation is critical to maximizing and defending these benefits.

At the same time, changes under Section 174 now require R&D costs to be capitalized and amortized, increasing near-term taxable income and making credits even more valuable. Additional incentives, such as the Orphan Drug Credit (25% of clinical trial costs) and state-level credits, can further enhance savings, with some states offering refundable or transferable credits. Strategic planning—such as where employees are located or where trials are conducted—can significantly impact total tax benefits. International trial locations may also offer incentives, but must be weighed against less favorable U.S. tax treatment of foreign R&D.

Beyond credits, long-term tax strategy plays a major role. Qualified Small Business Stock (QSBS) can eliminate federal taxes on gains after a 5-year hold, creating powerful alignment with R&D credits to reduce burn upfront and maximize exit value. Structuring the business correctly—ensuring the entity performing R&D retains IP rights and economic risk—is key to eligibility. Companies that proactively track projects, allocate costs accurately, and coordinate credits with broader tax strategy avoid common pitfalls and can unlock substantial cash savings. In practice, this can translate into hundreds of thousands of dollars in immediate benefit, materially extending runway and improving outcomes for both founders and investors.